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Abstract
Purpose To compare the success in repair of dural tears
(DTs) using two different surgical sealants in non-instru-
mented lumbar spinal surgery and evaluate the incidence of
associated short- and long-term complications.
Methods Twenty-three patients undergoing non-instru-
mented spinal surgery with intraoperative DTs were inclu-
ded both retrospectively and prospectively in this study.
External signs of CSF leakage, neurological deficits, and
infection-related complications were investigated postop-
eratively. The persistence of low-back pain was also eval-
uated and postoperative MRI was performed in all patients.
DTs were repaired intraoperatively using suture with or
without a dural patch. Eleven patients received an appli-
cation of fibrin glue (Tissucol; Baxter, Inc., IL, USA) and
12 patients received an application of bovine serum albumin
glutaraldehyde surgical adhesive (BioGlue Surgical
Adhesive; CryoLife, GA, USA). These patients were fol-
lowed up at 3 months and 1 year postoperatively.
Results Successful intraoperative DT repair was obtained
in all cases. Three patients in the Tissucol group presented
with CSF leakage in the early postoperative period. There
were no complications observed in the patients treated with
BioGlue. At 3-month follow-up, no incidences of neuro-
logical or infection-related complications were observed in
either group. There was no statistically significant differ-
ence in VAS between the two treatment groups.
Conclusions Intraoperative DTs can be easily repaired by
many effective techniques. However, in our experience, the
use of BioGlue is an effective adjunct to immediate dural
repair, being comparable in terms of efficacy and safety to
the use of fibrin glue, potentially decreasing the incidence
of associated short- and long-term complications.
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Introduction
Dural tear (DT) is the most frequent complication of spinal
surgery [1, 2]. DT rates in lumbar spinal surgery range
from 3.1 to 17.4 % [3–12]. Primary risk factors for DTs in
lumbar surgery are reoperation, prior irradiation, or
extensive degeneration of the lumbar spine [5]. These risk
factors cause dural fibrosis or scarring that makes manip-
ulation of the dural sac and root more difficult. Longer
operative times, use of instrumentation, and a less experi-
enced surgeon represent other significant risk factors for
DT [1, 10].
DTs are inevitably associated with cerebrospinal fluid
(CSF) leakage, causing subcutaneous CSF collections,
postural headaches, and an increased risk of infection-
related complications. DTs are frequently associated with
radicular impairment due to direct root damage or the
formation of a peri-radicular CSF pseudocyst and second-
ary spondylodiscitis [1–4, 9].
DTs are also associated with short- and long-term clin-
ical sequelae, such as longer recuperative bed rest times,
reoperations, extended inability to work, increased back
pain, and a higher frequency of postoperative complica-
tions such as headaches [9]. Nevertheless, it has been
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clearly reported that when a DT is recognized and suc-
cessfully repaired during surgery, it neither increases
morbidity nor affects clinical outcome [7].
Various methods have been successfully used to repair
DTs (suture, closed subarachnoid drainage, laser tissue
welding, muscle, fat or fascial grafts, blood patches, fibrin-
adhesive sealant, gel foam, and bed rest). A treatment can be
considered successful upon definitive repair of the DT and
resolution of CSF leakage, with no subsequent neurological
and infection-related complications. Intraoperatively, the
Valsalva maneuver can be used to test the integrity of a DT
repair, confirming a watertight seal has been achieved.
Moreover, a safe and effective treatment should not
result in prolonged bed rest time, which may lead to
complications such as deep vein thrombosis. This is of
particular importance in cases of benign degenerative
spinal disease, in which any complication or modification
of the normal clinical course should be avoided or
promptly resolved.
Materials and methods
Three hundred and twenty-one (321) patients undergoing
non-instrumented lumbar spinal surgery procedures,
including 218 microdiscectomy (MD) and 103 laminec-
tomy (LM), in our department from January 2005 to
August 2011 were included in this study. Data collected on
patients before 2009 were obtained from the retrospective
review of medical charts. After 2009, informed consent
was obtained for all patients.
Of these 321 patients, 54 (16.8 %) were undergoing a
reoperation (41 for recurrent herniated disc and 13 for
repeat LM). Twenty-three patients (7.1 %) experienced
DTs (13 patients undergoing MD and 10 undergoing LM).
Fifteen (65.2 %) of the patients who experienced DTs were
undergoing reoperations (9 patients undergoing MD and 6
undergoing LM). DTs involved radicular nerves in 12
cases, dural sac in 5 cases, and both in 6 cases.
In 16 cases of DT, primary repair was performed with
5–0 silk sutures; these cases included 5 lacerations of the
dural sac, 10 of radicular nerve, and 1 case of both. In the
remaining 7 cases (2 lacerations of axilla of radicular nerve
and 5 of extremely fragile dura with involvement of sac
and root dura), a small dural patch composed of equine
collagen (Tissudura; Baxter, Inc.; IL, USA) was laid over
the DT and partially sutured with 5–0 silk sutures. Two
different materials were used to reinforce the sutures. In 11
cases, a thick layer of Tissucol (Baxter, Inc.; IL, USA)
fibrin glue was applied to suture alone (n = 9) or dural
patch with suture (n = 2). Five patients had a radicular
durotomy, 4 had a dural sac laceration, and 2 had both.
Seven of these patients were undergoing reoperations. In
the remaining 12 cases, a thin layer of BioGlue Surgical
Adhesive (BioGlue; CryoLife; GA, USA) was applied to
suture alone (n = 7) or dural patch with suture (n = 5).
Seven patients had a radicular durotomy, 1 had a dural sac
laceration, and 4 had both. Eight of these patients were
undergoing reoperations.
Factors contributing to the complexity of dural repair
required are summarized in Table 1, grouped according to
the sealant used. Seven out of the 11 patients in the
Tissucol group (64 %) were reoperations, compared with 8
out of the 12 in the BioGlue group (67 %). Similarly, 4 out
of 11 procedures in the Tissucol group (36 %) involved
repairs associated with nerve laceration, compared with 6
out 11 in the BioGlue group (50 %). There were no sig-
nificant differences in baseline characteristics between the
two patient groups. Risk factors for CSF leaks, such as
reoperations and the presence of nerve lacerations, were
similar in both the Tissucol and BioGlue patients.
To test the integrity of the DT repairs and the absence of
any intraoperative CSF leakage, the Valsalva maneuver
was performed in triplicate for all cases.
After DT repair, the paravertebral fascial and subcuta-
neous muscles and skin layers were separately sutured. No
drains were inserted in any of the cases.
For those patients who experienced DTs, our protocol
prescribes that bed rest time is prolonged for at least 72 h,
compared to the standard 24 h, in absence of further
complications. During the immediate postoperative period,
signs of external CSF leakage or subcutaneous collections
were investigated. These patients underwent 3-month
and 1-year clinical, imaging, and laboratory follow-up.
Table 1 Summary of patient characteristics
Sealant Number of patients Type and number of procedures Reoperations Dural sac repair Nerve laceration Both procedures
Tissucol group 11 MD 7 4 1 2 1
LM 4 3 1 2 1
BioGlue group 12 MD 6 5 4 2
LM 6 3 1 2 3
Total 23 MD 13 9 1 6 3
LM 10 6 1 4 4
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The persistence of low-back pain was measured by Visual
Analog Scale (VAS) scoring; signs of adjunctive postop-
erative neurological deficits and infection-related compli-
cations were evaluated; erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) were investigated.
Magnetic resonance imaging (MRI) was performed to
detect CSF leaks, pseudocysts, spinal arachnoiditis, or late
spinal segment degeneration.
Results
Surgery and early postoperative period
In all 23 patients with DT, the dural defect was effectively
repaired intraoperatively, indicated by the absence of CSF
leakage. In two patients treated by dural patch, suture, and
Tissucol, Valsalva maneuvers, resulted in sealant dislodg-
ment, necessitating further reinforcement of the repair
using a second, more effective application of Tissucol,
before closing. In the group of 11 patients treated with
Tissucol, three experienced CSF leakage in the early
postoperative period. Two of them presented with external
CSF leakage on the second and sixth postoperative days,
respectively. These patients were initially treated with CSF
lumbar drainage and prolonged bed rest for 1 week. One
patient had resolution of CSF leakage; the other required a
reoperation for repair of the dural defect with BioGlue.
This surgical repair resulted in resolution of the CSF
leakage. The third patient with CSF leakage presented with
severe low-back pain on the tenth postoperative day owing
to early spondylodiscitis due to Staphylococcus aureus.
This patient required reoperation with debridement and
irrigation of the surgical wound and received a muscle and
fat patch sealed by Tissucol, which resulted in resolution of
the CSF leak.
Another patient treated with Tissucol, who did not
present with postoperative CSF leakage, experienced deep
vein thrombosis in the early postoperative period, which
was treated successfully with low molecular weight hepa-
rin for 3 months.
No signs of CSF leakage, either intra- or postopera-
tively, or neurological and infection-related complications
were observed in any of the patients treated with BioGlue.
The mean bed rest time for patients with DT who
experienced further complications (external CSF leak-
age, spondylodiscitis and deep venous thrombosis) was
15.2 days, and for patient with a successfully treated DT
was 6.2 days. The standard bed rest time for patients who
underwent non-instrumented lumbar surgery, without DT,
was 1.2 days (Fig. 1).
Three-month follow-up
At 3-month follow-up, there were no cases of neurolog-
ical complications observed in either group. Persistent
low-back pain was reported in 5 patients with a mean
VAS score of 45 (mean VAS score for all patients was
15); of these patients, 3 had been treated with Tissucol
and 2 with BioGlue. In particular, the patient who expe-
rienced spondylodiscitis continued to present with severe
low-back pain (VAS score of 65) without radicular
involvement and was treated with antibiotics and a stan-
dard lumbosacral orthotic brace. In this patient, pain is
most likely related to spondylodiscitis rather than du-
roplasty and sealant application. The patient who experi-
enced deep vein thrombosis in the early postoperative
period recovered and did not complain of low-back pain
at 3-month follow-up. ESR and CRP were normal in all
cases except for the patient with spondylodiscitis (ESR 25
and CRP 14).
One-year follow-up
At 1-year follow-up, 4 of the 5 patients who complained of
low-back pain at 3-month follow-up, continued to present
with discontinuous low-back pain, with a mean VAS score
of 26 (mean VAS score for all patient was 10); of these
patients, 2 had been treated with Tissucol and 2 with
BioGlue. No patients demonstrated any neurological defi-
ciencies. There was no statistically significant difference
found in mean VAS scores between treatment groups
(p [ 0.1).
MRIs performed during follow-up confirmed that there
were no cases of CSF leaks, pseudocysts or spinal arach-
noiditis. No signs of late spinal segment degeneration were
observed in either group, except for the patient with
spondylodiscitis who underwent L4–L5 anterior fusion due
to complete degeneration of the disc. No local or systemic
adverse reactions to Tissucol or BioGlue were observed
during the follow-up period (Fig. 2).
Fig. 1 Intraoperative photograph. A small dural patch composed of
equine collagen (Tissudura; Baxter, Inc., IL, USA) was laid over the
DT and a very thin layer of BioGlue Surgical Adhesive (BioGlue;
CryoLife, GA, USA) was applied to dural patch
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Discussion
DT is the most frequent complication of spinal surgery, and
has a higher tendency of occurring during dissection of the
epidural scar at reoperation [13, 14]. We believe that DTs
should be treated immediately and effectively to avoid
further complications.
Surgeons tend to have personal preferences for the
effective treatment of DTs, and the literature reports
many safe and long-standing surgical strategies as fol-
lows: sutures; closed subarachnoid drainage; prolonged
subfascial drain placement; laser tissue welding; muscle,
fat or fascial grafts; blood patches; fibrin adhesive or
cyanoacrylate polymer sealants; gel foam; autologous
fibrin tissue adhesive; polyglycolic acid mesh with fibrin
glue; and absorbable hydrogels such as DuraSealTM
[3, 13–18].
Surgical factors that could impede detection, successful
repair, and healing of DTs should be avoided. For example,
ADCON-L (Gliatech; OH, USA), a porcine-derived
polyglycan used in spinal surgery to reduce postoperative
epidural fibrosis and adhesion, may inhibit dural healing
and exacerbate CSF leakage from microscopic durotomies
that may be undetectable at the time of surgery [19].
Suturing the DT whenever possible appears to be an
important factor in the prevention of repeat surgery to
repair the defect [8]. Reoperation for dural repair is rec-
ommended when CSF leakage is noted in the early post-
operative period and is mandatory when the CSF leakage
does not resolve spontaneously or by lumbar drainage, or
when it is associated with signs of wound infection [20].
Immediate and effective repair of DT is particularly
important also because DT is reported to be the second
most frequent cause of medicolegal implications after
nerve root damage [21].
Our treatment protocol includes, as a first priority, the
watertight suture of the DT, if possible. Nevertheless, there
are some instances when suturing is technically difficult, as
in root axillary durotomies or in patients with fragile and
very thin or scarred dural layer. In such cases, we suggest
the partial suturing of a small dural patch to avoid any
further dural damage, followed by an application of a dural
sealant. The dural patch may be synthetic or biologic; in
the latter case, heterologous (bovine or equine) or autolo-
gous (muscle or fat) may be used.
At our institution, we utilize Tissucol and BioGlue as
dural sealants. They have different characteristics and
hence should be used in different manners. Tissucol is a
topical hemostat, composed of fibrinogen, aprotinin,
human thrombin, and calcium chloride. When Tissucol is
applied, a dense fibrin network is formed which facilitates
DT repair via its hemostatic properties. In contrast,
BioGlue forms covalent bonds with cell surface proteins
once in contact with the tissue. Because of the difference
between Tissucol and BioGlue in mechanism of action, a
thin layer of BioGlue is sufficient to achieve repair of the
DT without complications. In this patient series, Valsalva
maneuvers were performed before closure.
CSF leaks were observed at the repair sites in two
patients where Tissucol had been applied but had appar-
ently been dislodged. Reapplication of the sealant subse-
quently achieved full duroplasty. No CSF leaks were
observed following Valsalva maneuvers where BioGlue
was used for DT repair.
Although there were no significant differences in the
dural defects of the two groups, we speculate that DT
repairs with the use of BioGlue, due to its strong bonding
properties, make it more resistant soon after the application
to internal CSF pressure and pulses which could conse-
quently force the suture open, dislodge the applied sealant,
Fig. 2 Axial T2 (left) and T1
(right) MRI scans at L4-L5
level. The dorsal left portion of
dural sac has been repaired by a
thin layer of BioGlue (arrows).
No signs of extradural CSF
collection are evident. The thin
layer of BioGlue does not
produce any compression or
dislocation of dural sac or nerve
root
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and reopen the leak. Therefore, for a faster and more
confident technique for controlling CSF leakage during
surgery, we have moved increasingly toward the use of
BioGlue for DT repair at our institution.
Even in cases of effective treatment of DTs, as reported
in the literature, it was our common practice to prolong the
postoperative bed rest time, leaving the patient supine for a
few days [3, 22]. In this series, patients with complications
from DT and postoperative CSF leakage had a longer bed
rest time as compared to patients with successfully repaired
DT.
In our experience, a single, very thin layer of BioGlue is
sufficient to reinforce the dural repair site and to prevent
any secondary ruptures; it is also effective in assuring good
adhesion of the edges of the dural patch to the native
surrounding dura [23]. Furthermore, the gradual resorption
of BioGlue allows for sufficient time for local healing of
the DT [24]. Nevertheless, it is essential that a very thin
layer of BioGlue is applied; the application of larger
quantities may create a pooling of glue, potentially leading
to serious side effects, such as compression of the spinal
cord and nerve roots [25]. If used incorrectly, excess glue
may isolate a dead space at the surgical site from blood and
antibiotics, thus facilitating infections [26].
Toxic effects of BioGlue have been anecdotally
reported in the literature; these effects have been asso-
ciated with the possible development of aseptic menin-
gitis due to the glutaraldehyde component [23, 27].
However, it should be noted that the bovine serum
albumin (45 %) and glutaraldehyde (10 %) are mixed
together in the applicator tip to form the glue, after which
point the glutaraldehyde no longer exists as a single
component. Although the biocompatibility of this sealant
has been demonstrated, care should be taken to apply it
only extradurally [28].
BioGlue has been used extensively in neurosurgery, in
both cranial and spinal procedures [29]. It has been used
with particular success in preventing postoperative CSF
leaks in transsphenoidal surgery [30, 31]. In all our
patients, in both cranial and spinal surgery, we have never
experienced complications directly related to its use. Also,
since this is a retrospective study, a controlled comparison
of Tissucol to BioGlue in the repair of DT was not pos-
sible. This observational study shows that BioGlue use
was effective in intraoperative DT repair and did not
result in any complications. BioGlue has also been very
useful in select and challenging cases such as reoperation
in the posterior fossa, where a scarred and fibrotic dura
can lose its physiological elasticity and resilience, being
exposed to the mechanical stress and bulging of CSF
pulses [32].
Conclusion
BioGlue and Tissucol are effective and safe dural sealants,
allowing for immediate dural repair in non-instrumental
lumbar spinal surgery. When used appropriately and in an
informed manner, BioGlue can potentially reduce the
incidence of associated short- and long-term complications.
Further studies to evaluate the effects of BioGlue use on
the incidence of complications associated with the repair of
dural tears are warranted.
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